28 June 2018 EMA/CHMP/BPWP/94038/2007 Rev. 5 Committee for Medicinal Products for Human Use (CHMP)
Guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg)
Revised draft agreed by the Blood Products Working Party Adoption by CHMP for release for consultation
November 2016 15 December 2016
Start of public consultation
1 January 2017
End of consultation (deadline for comments)
31 March 2017
Revised draft agreed by the Blood Products Working Party
14 June 2018
Adoption by CHMP
28 June 2018
Date for coming into effect
1 January 2019
Guideline EMA/CHMP/BPWP/94038/2007 replaced guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg) with reference number CPMP/BPWP/859/95.
Keywords
IVIg, human normal immunoglobulin, primary and secondary immunodeficiency syndromes, hypogammaglobulinaemia, primary immune thrombocytopenia (= idiopathic thrombocytopenic purpura (ITP)), Guillain Barré syndrome, Kawasaki disease, multifocal motor neuropathy (MMN), chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact
Guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg) Table of contents Executive summary ..................................................................................... 3 1. Introduction (background) ...................................................................... 3 2. Scope....................................................................................................... 4 3. Legal basis .............................................................................................. 4
Guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg) EMA/CHMP/BPWP/94038/2007
Page 2/16
Executive summary This guideline describes the information to be included in the summary of product characteristics (SmPC) for human normal immunoglobulins for intravenous administration.
Guideline on core SmPC for human normal immunoglobulin for ...
Jun 28, 2018 - Each {container e.g. vial} of {xx} ml contains: {X} g of human normal .... vascular accident (including stroke), pulmonary embolism and deep.
Jun 1, 2016 - Reproduction is authorised provided the source is acknowledged. 26 May 2016 .... For the full list of excipients, see section 6.1. 104. 105. 106.
Jul 20, 2017 - Any marketing authorisation application or variation of a marketing .... The gallium (68Ga) chloride solution is not intended for direct use in ...
Apr 26, 2017 - 365 keV (81.7%), 637 keV (7.2%) and 284 keV (6.1%) and beta radiations of maximal ...... After entering the blood stream it is distributed in. 461.
Jun 1, 2016 - The completed comments form should be sent to .... radiation with a maximum energy of 634 keV followed by photonic annihilation radiations of 511 keV. 85. 86 ..... alternative techniques not using ionising radiation. 297.
Apr 26, 2017 - 28 publication of this core SmPC. However, this list of clinical settings does not waive the need to submit. 29 the required studies to support the ...
Jun 1, 2016 - 360. 361. [*For the printed material, please refer to the guidance of .... microbiological point of view, the product should be used immediately.
Jun 28, 2018 - Table of contents. Executive summary . ..... The patients selection should take into account statistical considerations. (see below). At least 40 ...
Invented name: Not Applicable. Latest Decision number(s):. 1) P/120/2010 2) ... Contact for inquiries from interested parties: Louise Pedreschi. Telephone:.
Notification of discontinuation of a paediatric development which is covered by an agreed ... for the following reason(s): (tick all that apply). (possible) lack of ...
Working cell bank/ secondary bank: culture of cells derived from a master cell bank and intended to. prepare production cultures. The working cell bank is usually kept at a temperature of -70°C or less. In. some countries, it is called the. Page 3 o
Jul 27, 2005 - ADRs may change throughout the patient's life-time according to age and .... Effective pharmacovigilance requires the efficient capture of data ...
Page 1/17. 16 May 2018 ... Page 2/17. E14 Q&As document history. Code ..... line s. 3. Nonclinical Data to Support Clinical Trial Design and. Marketing. 1. 3.1. 2.
14 Dec 2017 - ACPA. Anti-citrullinated peptide/protein antibodies. ACR. American College of Rheumatology. CCP. Anti-cyclic citrullinated protein/peptide. CDAI. Clinical Disease Activity Index. CHMP. Committee for Human Medicinal Products. CRP. C-reac
May 26, 2016 - process verification in terms of requirements (types of data, statistical approaches ...... due to ongoing development of analytical methods, not.
Nov 10, 2016 - versus extended prophylaxis); c) updated definition of bleeding events (e.g.: ... Studies in Support of Special Populations: Geriatrics (ICH E7 ...
Jul 14, 2016 - Committee for Medicinal Products for Veterinary Use (CVMP). Overview of .... infestation. Single housing is recognised to cause stress in social ..... Res Tech. 2013 .... development program for selection of a field isolate for.
Nov 10, 2016 - (e.g.: acutely ill non-surgical patients at high risk of VTE versus outpatients with ... radiotherapy has been performed in the previous 6 months.
Dec 8, 2016 - This guideline updates the âGuideline on quality data requirements for veterinary medicinal products ..... Final product batch analysis data.
May 27, 2016 - 383. â¢. Feed type, feeding regime and the veterinary history of the animals from which the manure. 384 originates (if data are available). 385.